NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our ...

RADNOR, Pa., March 31, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against Geron Corporation ("Geron") (NASDAQ: GERN) on behalf of those who purchased or otherwise acquired Geron securities between February 28, 2024, and February 25, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is May 12, 2025. The complaints allege that, throughout the Class Period, Defendants made false a ...

Core Viewpoint - Geron Corporation is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives misled investors regarding the performance and market potential of its primary product, Rytelo [1][3]. Company Overview - Geron Corporation is a commercial-stage biopharmaceutical company focused on developing therapeutic products for oncology, with its main product being a telomerase inhibitor called imetelstat, marketed as Rytelo [2]. Allegations of the Lawsuit - The lawsuit alleges that Geron and its executives made false or misleading statements about the company's revenue outlook and growth potential, downplaying risks associated with seasonality and macroeconomic factors [3]. - It is claimed that the optimistic reports regarding Rytelo's launch success did not reflect the reality of its market penetration challenges, including competition and a lack of awareness among potential patients [3]. - Following the announcement of financial results for Q4 2024, which indicated stagnant growth for Rytelo, Geron's stock price dropped over 32%, highlighting the impact of the alleged misrepresentations [4]. Legal Process - Investors who purchased Geron securities during the specified class period can seek to be appointed as lead plaintiff in the class action lawsuit, representing the interests of all class members [5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - Geron Corporation (NASDAQ: GERN) has experienced a potential plateau in the sales of its product Rytelo (imetelstat) shortly after its launch in mid-2025, which may be causing market concerns [1] Company Summary - Geron Corporation has only reported two full quarters of sales for Rytelo since its introduction [1] - The market appears to be reacting to the stagnation in sales growth following the product's launch [1]

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Geron Corporation (NASDAQ: GERN) securities between June 7, 2024 to February 25, 2025. Geron is a commercial-stage biopharmaceutical company with a focus on blood cancer. Geron's primary product is a telomerase inhibitor, imetelstat, which the Company sells under the brand name, Rytelo. Attorney Advertising. Past results do not guarantee ...

CONTACT US HERE: https://securitiesclasslaw.com/securities/geron-corporation-loss-submission-form/?id=139419&from=4 CLASS PERIOD: February 28, 2024 to February 25, 2025 ALLEGATIONS: According to the complaint, defendants provided investors with material information concerning defendants' expectations for the launch and growth potential of Rytelo (imetelstat). Defendants' statements included, among other things, confidence in Geron's ability to capitalize on the purportedly significant unmet need for the dru ...

Core Viewpoint - Securities class action lawsuits have been filed against Geron Corporation for allegedly misleading investors regarding its revenue outlook and product performance during the specified class period [1][3]. Group 1: Allegations Against Geron Corporation - Defendants allegedly created a false impression of reliable information regarding Geron's revenue outlook and growth potential while downplaying risks from seasonality and macroeconomic factors [3]. - Reports on the launch success and growth potential of Geron's primary product, RYTELO, were claimed to be overly optimistic and did not reflect the reality of market conditions, competition, and patient initiation challenges [3]. - RYTELO reportedly lacked market penetration awareness, hindering Geron's ability to meet the significant unmet need for the drug, especially among first-line patients [3]. - Statements made by the defendants regarding the company's business and prospects were claimed to be materially false and misleading [3]. Group 2: Legal Process for Investors - Geron investors can seek to be appointed as lead plaintiffs by May 12, 2025, through Kessler Topaz Meltzer & Check, LLP or other counsel [4]. - A lead plaintiff represents the interests of all class members and typically has the largest financial stake in the case [4]. - Investors who choose not to serve as lead plaintiffs can still participate in any recovery as absent class members [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Geron Corporation securities between February 28, 2024, and February 25, 2025, of the May 12, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Geron securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by May 12, 2025 [2] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [5] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Allegations - The lawsuit alleges that Geron Corporation made false and misleading statements regarding the market potential and profitability of its drug RYTELO, which were not disclosed to investors [4] - Key issues include a lack of awareness among healthcare providers, monitoring requirements, seasonality, and competition that would impair Geron's ability to capitalize on the drug's market potential [4] - As a result of these misrepresentations, Geron's business and financial prospects were overstated, leading to investor damages when the true information became public [4]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Geron To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in Geron between February 28, 2024 to February 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, March 28, 2025 /PRNewswir ...

LOS ANGELES, March 28, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Geron Corporation ("Geron" or "the Company") (NASDAQ: GERN) for violations of the federal securities laws.Shareholders who purchased the Company's securities between June 7, 2024 and February 25, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before May 12, 2025.     CASE DETAILS:  According to the Complaint the company allegedly made misleading statements that gave inv ...